FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2752003295> ?p ?o ?g. }

• W2752003295 endingPage "606" @default.
• W2752003295 startingPage "598" @default.
• W2752003295 abstract "Increasing evidence indicates that epidermal growth factor receptor (EGFR) has a pathogenic role in renal fibrosis. Currently no effective treatment can completely halt the progression of chronic kidney disease (CKD). This study was undertaken to investigate the renoprotective effects of erlotinib, a tyrosine kinase inhibitor that can block EGFR activity in the progression of CKD and the mechanisms involved.Sprague Dawley rats with 5/6 nephrectomy were administered either erlotinib or vehicle from 2 weeks after surgery and for a period of 8 weeks. Blood pressure, proteinuria and serum creatinine were measured periodically. Renal morphological investigations were performed at sacrifice. In vitro, we used normal human mesangial cells (NHMCs) and human proximal tubular cells to investigate the inhibitory effects of erlotinib on renal fibrosis-associated signaling pathways by western blotting.Erlotinib treatment significantly blunted the progression of CKD as evidenced by reduced levels of serum creatinine, proteinuria and renal cortical profibrogenic genes and scores of glomerulosclerosis and tubulointerstitial damage. Tubulointerstitial macrophage infiltration and multiple pro-inflammatory cytokine gene expression levels were also attenuated by erlotinib treatment. In vitro, heparin-binding epidermal growth factor-like growth factor-induced Akt and extracellular-regulated kinase (ERK) 1/2 activation in normal human mesangial cells and human proximal tubular cells was inhibited by pretreatment with erlotinib.EGFR blocking by erlotinib protected against renal fibrosis in 5/6 nephrectomized rats via inhibition of Akt and ERK 1/2 signaling pathways, which are associated with renal fibrosis. Erlotinib also has anti-inflammatory properties, which may contribute to its renoprotective effects. Erlotinib represents a potential novel therapeutic strategy for the treatment of CKD." @default.
• W2752003295 created "2017-09-15" @default.
• W2752003295 creator A5006288609 @default.
• W2752003295 creator A5015604499 @default.
• W2752003295 creator A5017269198 @default.
• W2752003295 creator A5023592217 @default.
• W2752003295 creator A5032159521 @default.
• W2752003295 creator A5033387432 @default.
• W2752003295 creator A5059817950 @default.
• W2752003295 creator A5064424624 @default.
• W2752003295 creator A5070202158 @default.
• W2752003295 creator A5085783938 @default.
• W2752003295 date "2017-09-07" @default.
• W2752003295 modified "2023-10-16" @default.
• W2752003295 title "Erlotinib attenuates the progression of chronic kidney disease in rats with remnant kidney" @default.
• W2752003295 cites W1548083421 @default.
• W2752003295 cites W1866571790 @default.
• W2752003295 cites W1974162922 @default.
• W2752003295 cites W1976693476 @default.
• W2752003295 cites W1981196636 @default.
• W2752003295 cites W1993931106 @default.
• W2752003295 cites W1995706668 @default.
• W2752003295 cites W1997776357 @default.
• W2752003295 cites W2000952200 @default.
• W2752003295 cites W2011610612 @default.
• W2752003295 cites W2011642803 @default.
• W2752003295 cites W2012060112 @default.
• W2752003295 cites W2018612646 @default.
• W2752003295 cites W2026909572 @default.
• W2752003295 cites W2033092347 @default.
• W2752003295 cites W2036926586 @default.
• W2752003295 cites W2061751751 @default.
• W2752003295 cites W2069250511 @default.
• W2752003295 cites W2071910136 @default.
• W2752003295 cites W2079869133 @default.
• W2752003295 cites W2084817237 @default.
• W2752003295 cites W2086331541 @default.
• W2752003295 cites W2086736746 @default.
• W2752003295 cites W2087789006 @default.
• W2752003295 cites W2091310109 @default.
• W2752003295 cites W2102832330 @default.
• W2752003295 cites W2105824620 @default.
• W2752003295 cites W2107751591 @default.
• W2752003295 cites W2107966408 @default.
• W2752003295 cites W2108558127 @default.
• W2752003295 cites W2109121204 @default.
• W2752003295 cites W2109143521 @default.
• W2752003295 cites W2109642121 @default.
• W2752003295 cites W2116367640 @default.
• W2752003295 cites W2120133142 @default.
• W2752003295 cites W2130289134 @default.
• W2752003295 cites W2130804465 @default.
• W2752003295 cites W2132782966 @default.
• W2752003295 cites W2134641700 @default.
• W2752003295 cites W2136849575 @default.
• W2752003295 cites W2143939800 @default.
• W2752003295 cites W2149994621 @default.
• W2752003295 cites W2160300792 @default.
• W2752003295 cites W2161541244 @default.
• W2752003295 cites W2167781127 @default.
• W2752003295 cites W2169981609 @default.
• W2752003295 cites W2171491576 @default.
• W2752003295 cites W2172125631 @default.
• W2752003295 cites W2198564483 @default.
• W2752003295 cites W2264782344 @default.
• W2752003295 cites W2286146897 @default.
• W2752003295 cites W2313156113 @default.
• W2752003295 cites W2340402224 @default.
• W2752003295 cites W2440513987 @default.
• W2752003295 cites W2485916939 @default.
• W2752003295 cites W4238271314 @default.
• W2752003295 doi "https://doi.org/10.1093/ndt/gfx264" @default.
• W2752003295 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28992288" @default.
• W2752003295 hasPublicationYear "2017" @default.
• W2752003295 type Work @default.
• W2752003295 sameAs 2752003295 @default.
• W2752003295 citedByCount "12" @default.
• W2752003295 countsByYear W27520032952018 @default.
• W2752003295 countsByYear W27520032952019 @default.
• W2752003295 countsByYear W27520032952020 @default.
• W2752003295 countsByYear W27520032952021 @default.
• W2752003295 countsByYear W27520032952022 @default.
• W2752003295 countsByYear W27520032952023 @default.
• W2752003295 crossrefType "journal-article" @default.
• W2752003295 hasAuthorship W2752003295A5006288609 @default.
• W2752003295 hasAuthorship W2752003295A5015604499 @default.
• W2752003295 hasAuthorship W2752003295A5017269198 @default.
• W2752003295 hasAuthorship W2752003295A5023592217 @default.
• W2752003295 hasAuthorship W2752003295A5032159521 @default.
• W2752003295 hasAuthorship W2752003295A5033387432 @default.
• W2752003295 hasAuthorship W2752003295A5059817950 @default.
• W2752003295 hasAuthorship W2752003295A5064424624 @default.
• W2752003295 hasAuthorship W2752003295A5070202158 @default.
• W2752003295 hasAuthorship W2752003295A5085783938 @default.
• W2752003295 hasBestOaLocation W27520032951 @default.
• W2752003295 hasConcept C121608353 @default.
• W2752003295 hasConcept C126322002 @default.
• W2752003295 hasConcept C134018914 @default.

• next